<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01042067</url>
  </required_header>
  <id_info>
    <org_study_id>2006-001895-18</org_study_id>
    <nct_id>NCT01042067</nct_id>
  </id_info>
  <brief_title>Safer Warfarin Treatment</brief_title>
  <acronym>CYKOWAR</acronym>
  <official_title>Safer Warfarin Treatment - the Influence of CYP2C9 Genotyping, Genotyping of Vitamine K Dependent Proteins and Dietary Vitamine K Status on Dosing, Clinical Effect and Adverse Events With Emphasis on the Initial Phase of Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oslo University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Oslo</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Norwegian Medicines Agency</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Norway: South-Eastern Norway Regional Health Authority</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Oslo University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is a national multicenter prospective observational study, including 200 patients.&#xD;
      The main purpose of this study is to explore in more detail the influence of genetic&#xD;
      variability (CYP enzymes and vitamin K dependent proteins) and dietary vitamin K status on&#xD;
      warfarin dosing, clinical effect and adverse events with emphasis on the initial phase of&#xD;
      treatment. The hypothesis is that genetic variability concerning CYP enzymes and vitamin K&#xD;
      dependent proteins predict dosing and adverse events during warfarin treatment. The main aim&#xD;
      is to individualize warfarin therapy and establish a treatment algorithm based on genotype&#xD;
      and dietary vitamin K status to make the anticoagulation therapy with warfarin more secure.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Suspended</overall_status>
  <why_stopped>
    Enrolling participants has halted due to lack of investigator.&#xD;
  </why_stopped>
  <start_date>January 2010</start_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Atrial Fibrillation</condition>
  <condition>Venous Thrombosis</condition>
  <condition>Pulmonary Embolism</condition>
  <condition>Heart Valve Prosthesis</condition>
  <arm_group>
    <arm_group_label>Warfarin treatment group</arm_group_label>
    <description>Open label study. Patients in need of warfarin treatment (standard indications) are included in the study at the onset of warfarin treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Blood specimens (whole blood, serum, plasma)</intervention_name>
    <description>The patients follow standard warfarin treatment regimens and the only intervention is the sampling of blood specimens.</description>
    <arm_group_label>Warfarin treatment group</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Whole blood, serum, plasma&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients in need of warfarin treatment (standard indications) are included in the study at&#xD;
        the onset of warfarin treatment. About 200 patients will be included.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Caucasian&#xD;
&#xD;
          -  &gt;18 years of age&#xD;
&#xD;
          -  included in the study at the onset of warfarin treatment&#xD;
&#xD;
          -  target INR (2-3 for atrial fibrillation, vein thrombosis, pulmonary embolism and&#xD;
             2.5-3.5 for prosthetic heart valves)&#xD;
&#xD;
          -  standard indications for warfarin treatment&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Non-caucasian&#xD;
&#xD;
          -  Clinical significant liver affection&#xD;
&#xD;
          -  Heart failure, NYHA class III-IV&#xD;
&#xD;
          -  Non-compliant - not able to accomplish protocol demands&#xD;
&#xD;
          -  Not able to give informed consent&#xD;
&#xD;
          -  Long-term antibiotic therapy&#xD;
&#xD;
          -  Malabsorption conditions and inflammatory bowel disease&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Oslo University Hospital</name>
      <address>
        <city>Oslo</city>
        <zip>N-0407</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <verification_date>April 2011</verification_date>
  <study_first_submitted>January 4, 2010</study_first_submitted>
  <study_first_submitted_qc>January 4, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 5, 2010</study_first_posted>
  <last_update_submitted>April 26, 2011</last_update_submitted>
  <last_update_submitted_qc>April 26, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 27, 2011</last_update_posted>
  <keyword>warfarin</keyword>
  <keyword>genotyping</keyword>
  <keyword>vitamin K</keyword>
  <keyword>dosing</keyword>
  <keyword>adverse events</keyword>
  <keyword>initial phase of treatment</keyword>
  <keyword>algorithm</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulmonary Embolism</mesh_term>
    <mesh_term>Atrial Fibrillation</mesh_term>
    <mesh_term>Thrombosis</mesh_term>
    <mesh_term>Embolism</mesh_term>
    <mesh_term>Venous Thrombosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

